Canada’s Drug Pricing Reform Faces Legal Challenge
Canada’s R&D drug industry says it approached the court as a “necessary step,” given the significant impact of the pricing reforms.
You may also be interested in...
A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.
Canadian pricing body, the PMPRB, is considering relaxing screening criteria for drugs that will be subject to stricter price controls and extending grace periods for conforming with new rules.
Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.